rather than changes in bilirubin excretion. However, it is only recently that we have had the technical capability of estimating changes in bile acid excretion and therefore practically all our concepts of hepatic excretion have been based on bilirubin metabolism. The situation is changing rapidly and it is already apparent that estimation of serum bile acid levels is a far more sensitive way of evaluating hepatic excretory function than the estimation of serum bilirubin levels. In particular a lot of liver disease in infancy and childhood is anicteric, and better methods must be found for early recognition of the problem. Figure 2 illustrates this point. Dr Saul Krugman was kind enough to give us thirty-six sera of patients exposed to hepatitis B virus. All of the samples were 0-2 ml which is the smallest volume ever analysed for bile acids. We used our published method (Ali and Javitt, 1970) Figure 3 illustrates the studies of Back and Ross (1973) . It (Anderson, Kok and Javitt, 1972) . More recently, Dr Uri Lavy (Lavy, Burstein and Javitt, 1973) has found that normal human meconium contains relatively large amounts of 26-hydroxycholesterol but no 70-hydroxycholesterol. Thus we believe that both pathways may exist in man.
Our interest in the metabolic pathways for bile acid synthesis came about when we found that monohydroxy bile acids had a special effect on bile flow . They completely suppress flow when given in large amounts. This phenomenon is illustrated in Fig. 4 There are a group of neonates who develop jaundice as part of a cholestatic syndrome early in life and often the hyperbilirubinaemia will fall spontaneously to levels of 34 mg/ %. Although they have patent bile ducts, they are often explored and it is common practice to do some type of venting procedure usually a choledochoenterostomy. Many of these infants will respond to either phenobarbital or cholestyramine and surgery should not be done until a diagnostic or therapeutic trial of these medications is carried out Figure 9 is an attempt to classify the types of defects that may be expressed clinically as a cholestatic syndrome. The definition of a cholestatic syndrome as a reduction in canalicular bile flow is operationally useful (Javitt, 1971 (Ballow et al., 1973) and perhaps these infants represent examples of defects in bile salt nondependent flow. Other instances occur in which cholestyramine appears to have a much more beneficial effect than phenobarbital (Sharp and Mirkin, 1972) . Since the only established effect of cholestyramine is its capacity to bind bile acids it implies that it may be correcting some aspect of bile salt transport and is therefore related to bile salt dependent flow.
Although monohydroxy bile acids have been found as the conjugated and sulphated derivative in the urine of infants with cholestatic syndromes, we have no precise idea of whether they initiate or perpetuate the cholestasis. Preliminary studies in animals (Javitt, 1973) indicates that the conjugated and sulphated compound do not affect bile flow but the situation could be very different in man.
Discussion
Dr Murphy of Birmingham expressed concern about using phenobarbitone in the presence of a possible metabolic defect in bile salt metabolism. It seemed possible that this might aggravate the situation by stimulating pathways which could, for example, increase production of monohydroxy bile salts. Dr Murphy felt cholestyramine might be the more appropriate agent to use. Dr Javitt stated that they have not carried out any studies on the effect of phenobarbitone on bile acid metabolism and agreed that one had to be aware of such theoretical possibilities, but pointed out that there were some children in whom phenobarbitone did seem to work.
He, too, much preferred cholestyramine since its action on bile salts in the bowel is known and also if serum bile salts were altered from its use it would be possible to speculate as to how this has happened. He suggested that both agents might be used in sequence and all possible parameters in bile salt metabolism measured. 
